With the development of new epigenetic drugs with increased sensitivity, specificity, and decreased toxicity it might be possible to upregulate EAAT2 expression in neurological disorders depending on the epigenetic modification that is involved in repression of EAAT2 expression. Here, SLC1A2 is linked to nervous system disorder.